Schizophrenia Prescribing Assignment —
Paliperidone Palmitate, Clozapine, or Lamotrigine?
Your assignment gives you a 27-year-old male with schizophrenia, three hospitalizations in one year, and a medication list of paliperidone palmitate, clozapine, and lamotrigine. You must select the right medication, justify why the others are wrong, work out a dosing schedule, write patient education, order appropriate labs, build a nonadherence plan, and produce mock prescriptions for Part 2. This guide maps each requirement so you know what to address — without writing the paper for you.
💊 Need expert help writing your psychiatric prescribing paper or nursing assignment?
Get Expert Help →What This Assignment Is Testing — and Why Students Miss Key Requirements
This assignment has eight distinct deliverables packed into a 4–5 page paper plus a separate mock prescription component. You must: (1) select the appropriate medication from the given list; (2) justify that selection with clinical reasoning; (3) explain why the other two medications are not appropriate; (4) detail the dosing schedule and therapeutic endpoint; (5) provide patient education on risks, benefits, and side effects; (6) identify required labs and diagnostics before prescribing; (7) describe how you will monitor efficacy and side effects; and (8) build a nonadherence assessment and alternative treatment plan. Students who write a general pharmacology paper without engaging all eight tasks specifically — and without showing clinical decision-making rooted in this patient’s presentation — are missing what the rubric grades.
The clinical core of this assignment is the medication selection question, but the most graded section is often the nonadherence plan. The case is designed around a patient whose symptoms respond well to paliperidone but who cannot reliably take a daily oral medication. That setup makes the adherence question central — and your paper should treat it that way. The medication selection leads into the adherence solution, and the nonadherence plan is not a separate topic but the logical continuation of the same clinical problem.
Part 2 — the mock prescriptions — is a distinct deliverable that many students underestimate. Four prescriptions, each on its own page, formatted as a real prescription pad would be. This is a skills demonstration, not a filler section. Format, controlled substance scheduling, DEA number placement, sig notation, and refill limits all matter here.
Read the Case Twice Before You Do Anything Else
The case for Patient 5 contains specific clinical details that must drive every section of your paper. The patient is 27, male, has been hospitalized three times in one year, becomes disorganized and paranoid when symptomatic, responds to auditory hallucinations, has delusions about food being poisoned (with food refusal lasting multiple days), and has inadvertently harmed his mother during a psychotic episode. His symptoms are described as responding well to paliperidone — and his problem is memory and adherence, not medication efficacy. Each of these details is a clinical data point that should appear in your rationale, your education section, your lab decisions, and your nonadherence plan. A paper that treats the case as generic schizophrenia without engaging these specifics will not score at the top of any rubric.
Understanding What This Patient Case Is Telling You Clinically
Before selecting a medication, you need to understand what each clinical detail in the case means for your decision-making. This is not a case that requires you to figure out a diagnosis or trial a new agent blindly. The diagnosis is established (schizophrenia), the effective medication is identified (paliperidone), and the problem is stated explicitly (he struggles to remember to take it). Your paper’s job is to show clinical reasoning around those facts — not to restate them.
Reading the Clinical Data in This Case — What Each Detail Means for Your Paper
Every item in the case description has clinical significance. Your paper should demonstrate you understand what each one means for treatment decisions.
Three Hospitalizations in One Year
- Indicates severe illness with significant functional disruption — this is not a mild or stable presentation
- Justifies aggressive treatment optimization, not watchful waiting
- Raises the stakes for adherence failure — another hospitalization carries personal, financial, and safety costs
- Supports the case for a long-acting injectable over oral medication, as each hospitalization likely corresponded to a period of nonadherence
Paranoia, Disorganization, Auditory Hallucinations
- These are positive symptoms of schizophrenia — the domain where second-generation antipsychotics like paliperidone have established efficacy
- Auditory hallucinations that drive behavior (screaming at night after seeing a shadow) indicate the hallucinations are commanding or at minimum highly distressing
- Disorganization affects the patient’s ability to manage a complex oral regimen — further reinforcing the LAI rationale
- No mention of negative symptoms or cognitive deficits as primary complaints — relevant because clozapine’s advantage is partly in treatment-resistant cases with prominent negative symptoms
Delusions About Poisoned Food — Days Without Eating
- Food refusal lasting multiple days is a medical safety concern — nutritional compromise, dehydration, and weight loss can develop quickly
- This specific delusion may affect the patient’s willingness to take oral medication — if food is “poisoned,” pills may be viewed with the same suspicion
- This detail strengthens the LAI rationale: a once-monthly injection does not require the patient to trust a pill every day
- Your education section should address this delusion pattern directly and explain how to approach the patient about medication trust
Accidental Harm to Mother During Psychotic Episode
- This raises risk assessment considerations — the patient has demonstrated behavioral dyscontrol during psychosis, even without intent to harm
- It places the mother in the care environment as a key collateral contact — she must be included in your collaboration and education section
- It reinforces the urgency of preventing relapse through consistent medication delivery
- Your paper should address safety planning for the household, not just medication management
Symptoms Treated “Very Well” with Paliperidone
- This is the key clinical fact that drives the medication selection — established efficacy rules out the need to trial a different agent
- Switching to clozapine would require failing two adequate antipsychotic trials — this patient has not met that threshold
- The word “very well” indicates this is not a treatment-resistant case — clozapine’s niche is treatment-resistant schizophrenia
- Your rationale must use this history of response as the foundation for choosing paliperidone palmitate over the other options
“Struggles to Remember” — The Adherence Problem
- The stated barrier is memory, not refusal — this is an important distinction for your education and nonadherence sections
- Memory-based nonadherence in a patient with disorganized thinking is better addressed through structural solutions (LAI) than motivational ones alone
- Your nonadherence plan must address what “struggles to remember” looks like in practice and what systems will replace the memory requirement
- Family involvement, outpatient injection scheduling, and case management are all relevant here
When you write your paper, every section should trace back to specific elements of this case. A medication selection section that explains paliperidone palmitate without referencing the patient’s history of oral paliperidone response, his three hospitalizations, and his adherence barrier is generic. The assignment is testing whether you can apply pharmacological knowledge to a specific patient — not whether you can summarize paliperidone palmitate in the abstract.
How to Frame the Medication Choice — and How to Argue Against the Other Two Options
The assignment requires you to select the appropriate medication from the three listed and explain why the other two are not appropriate. This is not a comparison exercise where you weigh pros and cons of each — it is a clinical argument where you identify one clinically defensible choice and articulate specific reasons the other two do not fit this patient’s situation. The argument for your chosen medication and the argument against the others should be grounded in this patient’s presentation, not in abstract pharmacology.
The selection question is not which drug is best in general. It is which drug is right for this patient, given what he has already responded to, what his primary barrier is, and what the risk-benefit profile of each option looks like for him specifically.
— The clinical reasoning frame your paper requiresPaliperidone Palmitate — Why This Fits
The case states explicitly that the patient responds very well to paliperidone. Paliperidone palmitate is the long-acting injectable (LAI) formulation of the same active moiety — it eliminates the daily oral dosing burden that is driving his relapses. A once-monthly (or once-every-three-months with PP3M) injection delivered at a clinic visit solves the adherence problem structurally. No other change in the treatment plan addresses the root cause of his hospitalizations as directly. Your paper should explain the pharmacokinetic basis for why an LAI removes the adherence variable, not just state that it does.
Clozapine — Why This Does Not Fit
Clozapine is reserved for treatment-resistant schizophrenia — defined as inadequate response to at least two adequate trials of antipsychotics. This patient has not met that threshold; his symptoms respond very well to paliperidone. Beyond indication, clozapine carries a black box warning for agranulocytosis requiring mandatory REMS enrollment and regular CBC monitoring. It also causes significant metabolic side effects, sedation, and carries risk of myocarditis and seizures. Prescribing clozapine when an effective, better-tolerated option exists is not evidence-based. Your paper must make this argument with specific reference to treatment-resistance criteria and the REMS monitoring burden.
Lamotrigine — Why This Does Not Fit
Lamotrigine is an antiepileptic agent approved for bipolar disorder and epilepsy. It has no FDA indication for schizophrenia monotherapy. The literature on lamotrigine as an adjunct in schizophrenia is limited and mixed — some evidence suggests it may help with negative symptoms when added to clozapine, but it is not a standalone antipsychotic agent. Prescribing it as the primary treatment for a patient with florid positive symptoms (hallucinations, paranoia, delusions) is not clinically supported. Your paper should name the absence of FDA indication for schizophrenia and explain that lamotrigine does not target the dopaminergic pathways underlying positive psychotic symptoms.
How to Structure Your Medication Rationale Section
Do not write three parallel sections — one for each drug — and leave the reader to draw conclusions. Write a primary argument for paliperidone palmitate first, grounded in this patient’s response history and adherence problem. Then address each of the rejected medications in a paragraph that explains the specific reason it is contraindicated or inappropriate for this patient. The section should move from “why this drug fits” to “why those drugs do not” — not from “here are the three options” to “I picked one.” The reasoning structure matters as much as the conclusion.
Dosing Schedule for Paliperidone Palmitate — What to Include and How to Explain It
The assignment asks you to explain the dosing schedule for this specific patient, including the therapeutic endpoint. This requires more than copying the prescribing information — it requires you to apply the dosing protocol to a patient who is transitioning from oral paliperidone, to explain the initiation sequence, and to define what clinical improvement looks like as the treatment goal.
| Phase | What Happens | What Your Paper Should Explain |
|---|---|---|
| Initiation — Day 1 | Loading dose of 234mg deltoid injection. The deltoid injection site is required for the loading doses because deltoid administration produces higher and faster peak plasma levels than gluteal — which is critical to establishing therapeutic levels quickly without requiring oral overlap in most patients | Explain why the deltoid is specified for initiation and what the pharmacokinetic rationale is. This demonstrates understanding of why the protocol is designed the way it is, not just what it says |
| Initiation — Day 8 (±4 days) | Second loading dose of 156mg deltoid injection. The two-injection initiation sequence is designed to rapidly achieve and sustain therapeutic plasma concentrations of paliperidone | Note the ±4 day flexibility window — this is clinically important for a patient who may miss appointments. Explain that this flexibility exists and what to do if the window is missed |
| Maintenance — Monthly | Maintenance doses range from 39mg to 234mg monthly, administered to either deltoid or gluteal muscle. The typical starting maintenance dose after the loading sequence is 117mg monthly, adjusted based on response and tolerability | Specify which dose is appropriate for this patient given his prior oral paliperidone response — this requires you to discuss the dose equivalence conversion from oral to injectable. Explain that dose adjustments are made based on symptom response and side effects, not on a fixed schedule |
| Renal Adjustment Consideration | Paliperidone is renally cleared — dose reduction is required for patients with CrCl below 80 mL/min. At baseline this patient is young (27), but renal function must still be confirmed before initiating | Include this as a reason why baseline renal function labs are required. A paper that prescribes without addressing renal clearance is clinically incomplete |
| Therapeutic Endpoint | The goal is remission of positive symptoms — resolution of auditory hallucinations, paranoid ideation, and disorganized thinking — sustained without hospitalization. Functional improvement (ability to engage in daily activities, maintain relationships, reduce family burden) is a secondary endpoint | Define remission criteria specifically for this patient — what would “success” look like? Reference symptom rating scales (PANSS or BPRS) as the standard clinical measurement tools. Connect the endpoint to his specific symptoms: no further food refusal episodes, no nighttime behavioral disturbances, no further unintentional harm events |
Do Not Just Quote the Prescribing Information
A dosing section that reproduces the prescribing information without applying it to this patient’s situation earns partial credit at best. The assignment asks for the dosing schedule for this specific patient. That means you need to address the transition from oral paliperidone to the injectable, explain the initiation sequence in terms the patient and family can understand, note the renal clearance requirement, and define what therapeutic success looks like for this individual — not for schizophrenia patients in general.
How to Write the Patient Education Section — Risks, Benefits, Side Effects, and Family Involvement
The assignment requires patient education covering risks, benefits, and potential side effects. For this patient, the education section has a unique challenge: the patient has paranoid delusions about food being poisoned. This means you cannot assume a standard therapeutic alliance where the patient automatically trusts medication recommendations. Your education section must acknowledge this and describe how to engage the patient — and his mother — in a way that addresses the paranoia without reinforcing it.
Benefits to Communicate to This Patient
- The medication is the same one that has worked well for him before — he knows from experience that it reduces the experiences he finds distressing
- The injection format means he does not have to remember a daily pill — removing a major source of failure in his prior regimen
- Consistent medication levels from the LAI mean more stable symptom control than peaks and troughs from daily oral dosing
- Stable symptom control reduces the risk of hospitalization — which is disruptive and frightening for both patient and family
- With consistent medication, the experiences he finds frightening (the shadows, the voices, the fear about food) are likely to reduce or stop
Risks and Side Effects to Address
- Injection site reactions — pain, swelling, and induration at the deltoid or gluteal injection site; explain these are usually mild and temporary
- Extrapyramidal symptoms (EPS) — akathisia, stiffness, tremor; explain what these feel like and that they can be managed with dose adjustment or adjunctive medication
- Metabolic effects — weight gain, elevated blood glucose, dyslipidemia; explain that labs will monitor for these and why diet and exercise matter
- Prolactin elevation — gynecomastia, galactorrhea, sexual dysfunction; discuss as relevant given his age
- QTc prolongation — explain the cardiac monitoring rationale without alarming the patient unnecessarily
- Sedation — discuss the importance of caution with driving or operating machinery especially at initiation
Family and Collateral Education — The Mother Is a Key Target
The assignment explicitly asks you to consider collaboration and education for family members, home health care, and primary care providers. The mother in this case is not just a bystander — she has been injured during a psychotic episode and is clearly the primary support person at home. Your education section for the family should address: what to expect during the initiation period, warning signs of relapse to watch for between injection appointments, what to do if the patient shows signs of food refusal or paranoid escalation before the next injection, and how to call for help safely if behavioral dyscontrol occurs again. The family needs a safety plan, not just medication information.
Required Labs and Diagnostics Before Prescribing — and What Each One Is Monitoring
The assignment asks for the labs and additional diagnostics needed prior to prescribing. For each lab you list, your paper should explain what it is measuring and why it is specifically required for this medication with this patient. A list of lab names without clinical explanation will not score at the top of a rubric that grades understanding.
| Lab / Diagnostic | What It Monitors | Why It Matters for This Patient and Medication |
|---|---|---|
| Fasting blood glucose and HbA1c | Baseline glycemic status and longer-term glucose control | Second-generation antipsychotics including paliperidone are associated with glucose dysregulation and new-onset diabetes. Baseline measurement is required to distinguish pre-existing impairment from medication-induced changes at follow-up |
| Fasting lipid panel | Total cholesterol, LDL, HDL, triglycerides | Antipsychotics — particularly second-generation agents — are associated with dyslipidemia. A 27-year-old male with multiple hospitalizations may have had limited primary care contact; baseline lipids may be unknown |
| Weight and BMI | Baseline body composition for metabolic monitoring | Not a lab, but a required baseline measurement. Paliperidone carries weight gain risk. Baseline BMI allows monitoring for clinically significant gain (≥7% of body weight) at follow-up intervals |
| BUN and serum creatinine (renal function) | Glomerular filtration rate estimation (eGFR) | Paliperidone is predominantly renally cleared — dose adjustment is required for CrCl below 80 mL/min. This is a mandatory pre-prescribing check, not optional even in young patients |
| CBC | Complete blood count — WBC, RBC, platelets | Baseline CBC is standard for antipsychotic initiation. It is especially important if clozapine is ever considered as an alternative — having a baseline WBC is essential for establishing any future leukopenia |
| Comprehensive metabolic panel (CMP) | Liver function, electrolytes, kidney function | Baseline liver function identifies any pre-existing hepatic impairment that could affect drug metabolism. Electrolyte abnormalities from days of food refusal should be corrected before initiating |
| ECG (electrocardiogram) | QTc interval at baseline | Paliperidone carries a QTc prolongation risk. A baseline ECG identifies patients with pre-existing prolongation who require closer cardiac monitoring or dose restriction. Relevant given the patient’s episodic food restriction, which can cause electrolyte disturbances affecting cardiac conduction |
| Prolactin level | Baseline prolactin | Paliperidone is a potent prolactin elevator. Baseline measurement allows attribution of any subsequent hyperprolactinemia to the medication. Relevant for a 27-year-old male given sexual and endocrine side effect risk |
| AIMS (Abnormal Involuntary Movement Scale) | Baseline extrapyramidal symptom assessment | Not a lab but a required clinical assessment. The AIMS documents any pre-existing movement abnormalities so that treatment-emergent tardive dyskinesia can be distinguished from pre-existing movement disorder at follow-up |
How to Monitor Efficacy and Side Effects — What to Track and How Often
The assignment asks how you would monitor both efficacy and side effects. These are two distinct monitoring tasks that require different tools and different timelines. Efficacy monitoring tracks whether the treatment is achieving the therapeutic endpoint. Side effect monitoring tracks whether the medication is causing harm that outweighs its benefit. Your paper needs to address both with specific intervals and specific clinical tools — not just say “follow up regularly.”
Tracking Symptom Response Over Time
Use structured symptom rating scales at each injection appointment. The Positive and Negative Syndrome Scale (PANSS) or the Brief Psychiatric Rating Scale (BPRS) provides quantifiable tracking of positive symptom severity. Document specifically: frequency and intensity of auditory hallucinations, paranoid ideation about food, nighttime behavioral disturbances, and any incidents of agitation or unintentional aggression. Compare at each visit against baseline. A reduction of ≥20% on PANSS positive subscale is often used as the threshold for clinically meaningful response.
Tracking Side Effects on a Schedule
Repeat fasting glucose and weight at 4 weeks, 8 weeks, and 12 weeks after initiation, then quarterly. Repeat lipid panel at 3 months and annually. Monitor blood pressure at each injection visit. These intervals follow the Metabolic Monitoring Protocol for Second-Generation Antipsychotics (Mount Sinai protocol) widely cited in psychiatric prescribing literature. Your paper should name the monitoring schedule explicitly and explain why each interval is chosen.
Tracking Extrapyramidal Side Effects
Repeat the AIMS scale at 6 months and then annually. At each injection visit, screen for akathisia using the Barnes Akathisia Rating Scale (BARS) or a clinical inquiry about restlessness. Stiffness and tremor should be assessed clinically. If EPS emerge, document severity and discuss dose reduction, switching injection site, or adding a low-dose anticholinergic agent. Tardive dyskinesia, once established, may be irreversible — early detection is the primary protection.
Include the Injection Visit as a Monitoring Opportunity
A significant advantage of a long-acting injectable over oral medication is that the injection visit creates a structured clinical contact point every four weeks. Your monitoring plan should leverage this — each injection appointment is an opportunity for symptom assessment, side effect screening, weight measurement, blood pressure check, and brief mental status examination. For this patient, the monthly visit also provides a regular opportunity to engage the mother or other family supports and assess the home environment. Frame the monitoring plan around the injection schedule — it is one of the LAI’s structural advantages beyond adherence.
How to Write the Nonadherence Section — Assessment, Alternative Plan, and Clinical Reasoning
The assignment asks what you would need to include in your assessment for a patient who may become nonadherent, and what alternative treatment solutions would follow. This is the section most students approach generically — describing nonadherence in schizophrenia broadly rather than thinking through what nonadherence looks like specifically when the prescribed treatment is a long-acting injectable. The paliperidone palmitate selection has already addressed the oral adherence problem. The nonadherence question here is about what happens if the patient refuses or misses his injection appointments.
| Nonadherence Scenario | Assessment Questions | Alternative Treatment Response |
|---|---|---|
| Patient refuses the first injection or subsequent injection appointments | Is the refusal driven by paranoia (the injection is harmful or poisoned)? By fear of needles? By lack of insight into illness? By a specific logistical barrier (transportation, work schedule)? Each driver requires a different response — motivational interviewing for insight-related refusal, needle desensitization for phobia, case management for logistical barriers | If the patient refuses injectable paliperidone outright, the alternative oral antipsychotic with the most adherence-friendly profile should be considered — options include long half-life oral agents (aripiprazole) or an intensified care model with daily dispensing at a pharmacy or community mental health center. Assertive Community Treatment (ACT) teams can provide medication supervision in the home |
| Patient misses an injection appointment by more than the allowed window | How long has it been since the last injection? Paliperidone palmitate has a long half-life, and the manufacturer provides guidance for re-initiation depending on how much time has elapsed. Was the missed appointment during a period of emerging psychosis, or was it logistical? Has the patient been taking any oral supplementation in the interim? | Follow the prescribing information’s re-initiation protocol for the specific number of days elapsed since last injection. For significant lapses (more than the recommended window), treat as a new initiation with the Day 1/Day 8 loading sequence. Document the missed appointment and the rationale for re-initiation protocol used |
| Patient shows emerging symptoms despite receiving injections | Is this breakthrough psychosis despite adequate plasma levels (true inadequate response), or has something changed — dose, site, or concurrent medication? Are there new stressors or substance use that might be driving symptom exacerbation? Has renal function changed, affecting drug clearance? | If breakthrough symptoms occur with confirmed injection adherence, reassess the dose — consider moving to a higher maintenance dose within the approved range. If symptoms persist at maximum LAI dose, this would be the first indication that treatment resistance may be emerging — at that point, a systematic reassessment including clozapine eligibility would be warranted |
| The mother or household can no longer support injection scheduling | Is there another family support? Can the patient attend the outpatient clinic independently with prompts? Is ACT or intensive outpatient support available in this patient’s area? | Build a care team that does not rely entirely on one family member. Connect the patient with a community mental health center, peer support specialist, or ACT team that can provide outreach. If social supports collapse completely, a more supervised living arrangement (supported housing, group home) may be the appropriate next step |
Structure the Alternative Treatment Plan as a Real Clinical Decision Tree
The assignment asks for a “new treatment plan” — not a paragraph about how you would encourage adherence. Write the alternative plan as a clinical decision: if the patient becomes nonadherent with paliperidone palmitate injections despite ACT support, then the next step is X, with the following dosing, monitoring, and coordination requirements. Name the alternative agent, explain why you chose it as the next option, and address how the monitoring plan would change. The nonadherence section should read like a clinical contingency protocol — specific, actionable, and evidence-referenced.
How to Write the Mock Prescriptions — What Must Appear on Each One
Part 2 requires four prescriptions — one per page — formatted as a real prescription pad. The patient is Jane Doe, DOB 1/1/2001, and the duration for all prescriptions is 3 months. This section is a clinical skills demonstration. The format must be complete and accurate. Incomplete prescriptions that would be rejected at a pharmacy do not demonstrate prescribing competency.
Required Elements on Every Prescription — and What Each One Means
A real prescription must contain all of the following. Missing any one element makes it invalid at the point of dispensing.
Who Is Writing the Script
- Your name and credentials (use your own name and PMHNP or appropriate credentials for this assignment)
- Practice address and phone number
- NPI number (you can use a placeholder for the assignment)
- DEA number — required for controlled substances. For this prescription set, lorazepam and methylphenidate are controlled; the others are not. Only include DEA number where required
Who the Script Is For
- Patient name: Jane Doe
- Date of birth: 1/1/2001
- Patient address (use a placeholder)
- Date the prescription is written — use today’s date or a plausible clinical date
What Is Being Prescribed
- Drug name (generic preferred in most clinical settings, brand acceptable)
- Strength — e.g., sertraline 100mg
- Dosage form — tablet, capsule, etc.
- Quantity to dispense — for a 3-month supply, calculate based on the sig
- Sig (directions): written in standard abbreviation format — e.g., “1 tablet PO QD” or “1 tablet by mouth once daily”
How Many Times the Script Can Be Filled
- For controlled substances (lorazepam, methylphenidate): 0 refills on a single prescription — controlled substances require a new prescription each time in most states
- For non-controlled substances (sertraline, aripiprazole): refills for a 3-month supply may be 0–2 depending on how you calculate the quantity
- Note that Schedule II controlled substances (methylphenidate ER) cannot have refills by federal law — write “0 refills” explicitly
Diagnosis on the Prescription
- Some prescriptions include the diagnosis or indication — particularly useful for insurance adjudication
- The assignment provides the indication for each medication: depression (sertraline, aripiprazole), panic attacks (lorazepam), ADHD (methylphenidate)
- Include the indication on the prescription as stated in the assignment — this also helps demonstrate you understand what each medication is being used for
Validation of the Script
- A prescription is not valid without a handwritten or authenticated signature
- For this assignment, sign your name — or type it with a line indicating where the signature goes
- For controlled substances, some states require a “dispense as written” or “substitution permissible” checkbox — include this field even if left blank
Methylphenidate ER Is a Schedule II Controlled Substance — Handle It Correctly
Methylphenidate ER (54mg) is a Schedule II stimulant. Schedule II controlled substances cannot be refilled — each dispensing requires a separate prescription. The DEA number of the prescriber is required. Some states require tamper-resistant paper for Schedule II prescriptions. Your mock prescription for methylphenidate must include the DEA number, must specify 0 refills, and should note the Schedule II status. Lorazepam is Schedule IV — still controlled, still requires the DEA number on the prescription, but may have limited refills depending on state law. Sertraline and aripiprazole are not controlled substances and do not require a DEA number.
How to Structure Your 4–5 Page Paper — a Section-by-Section Breakdown
At double spacing with 12-point font and one-inch margins, 4 pages holds approximately 1000 words of body text and 5 pages holds approximately 1250 words. That is enough space to address all eight requirements with meaningful depth — but not enough to be verbose in any section. Every paragraph must do work. Structure your paper so that each requirement gets its own clearly identifiable section, and each section uses the patient’s specific details rather than general pharmacology content.
One short paragraph. Introduce the patient case with key clinical details — diagnosis, symptom profile, history of response to oral paliperidone, and the adherence problem. End with a statement of the clinical question: which formulation, at what dose, with what plan, for a patient whose primary barrier is adherence. This orients the reader to the paper’s analytical task without restating the entire case description.
Two paragraphs. First paragraph: the argument for paliperidone palmitate, grounded in the patient’s response history, the adherence barrier, and the pharmacokinetic advantages of the LAI. Second paragraph: the argument against clozapine and lamotrigine, with specific reference to treatment-resistance criteria (for clozapine) and absence of indication (for lamotrigine). Both paragraphs should cite peer-reviewed evidence — not just clinical reasoning.
Two to three paragraphs. Cover the initiation sequence, maintenance dosing, therapeutic endpoint, required pre-prescribing labs (with rationale for each), and the monitoring plan. These three requirements are closely connected and can be addressed in adjacent paragraphs that follow a logical clinical sequence: before prescribing (labs) → prescribing (dosing) → after prescribing (monitoring). This saves space and demonstrates clinical workflow thinking.
One to two paragraphs. Patient education (risks, benefits, side effects) and family/provider collaboration addressed together. This section must address the mother explicitly, discuss the paranoid delusion context that affects medication trust, and name what other providers (primary care, community mental health, ACT) should be looped into the care plan and why. Generic education points without patient-specific application will not score well.
One to two paragraphs. Nonadherence assessment for this specific patient — what it looks like, how you identify it early, and what the clinical triggers for escalation are. Then a concrete alternative treatment plan if LAI adherence fails. Conclude with a brief restatement of the clinical rationale tying the medication choice to the adherence solution. Do not end on a generic statement about the importance of medication adherence — end on the specific plan for this patient.
Pre-Submission Checklist for This Assignment
- Your paper identifies paliperidone palmitate as the selected medication with a clinical rationale specific to this patient’s response history and adherence barrier
- You have explained why clozapine is not appropriate with reference to treatment-resistance criteria
- You have explained why lamotrigine is not appropriate with reference to its lack of FDA indication for schizophrenia
- The dosing section includes the initiation sequence (Day 1 and Day 8 loading doses) and specifies a maintenance dose with rationale
- The therapeutic endpoint is defined specifically for this patient — not as “symptom improvement” generically
- Labs are listed with the rationale for each one — not just a bullet list of lab names
- Patient education addresses the paranoid food delusion context as it affects medication trust
- The mother is named as a key collaboration target and given specific information
- The nonadherence section addresses injection-specific nonadherence scenarios, not just oral medication barriers
- The alternative treatment plan names a specific next step with clinical reasoning
- Five peer-reviewed, evidence-based references are included — outside of course resources
- Part 2 prescriptions include all required elements (prescriber info, patient info, drug details, sig, refills, signature, DEA number where required)
- Methylphenidate ER is written as 0 refills with DEA number included
- Paper is formatted in APA style with a reference page
The Most Common Errors on This Assignment — and How to Avoid Them
| # | The Error | Why It Costs Marks | The Fix |
|---|---|---|---|
| 1 | Writing about schizophrenia and antipsychotics generally instead of about this patient’s case specifically | A paper that summarizes pharmacology of the three drug options without applying clinical reasoning to the specific patient is a literature review, not a clinical paper. Every section of this assignment asks you to tie the content to Patient 5’s presentation | After every paragraph, ask: does this paragraph show I understand what this patient’s situation is and why this clinical decision is right for him specifically? If the paragraph would make equal sense for any patient with schizophrenia, it is not specific enough |
| 2 | Treating the mock prescriptions as secondary to the paper — formatting them poorly or omitting required elements | Part 2 is a distinct assessed component. Missing DEA number on controlled substances, wrong refill count, absent sig notation, or prescriptions that are missing the prescriber’s credentials will lose marks on a technical skills rubric | Look up a blank prescription template and ensure every field is populated. Write each prescription as if a real pharmacist would receive it — would they fill it? If not, something is missing |
| 3 | Listing labs without explaining why each one is required for this medication and this patient | A bullet list of lab names demonstrates you know which labs to order. An explanation of why each one is required demonstrates you understand what you are monitoring for and why it matters — which is the clinical reasoning the assignment grades | For each lab, write one sentence connecting it to paliperidone’s specific risk profile or this patient’s specific clinical situation. The renal function test is required because paliperidone is renally cleared — not just because it is standard practice |
| 4 | Nonadherence plan that describes oral medication reminders for a patient now on an injectable | The most common nonadherence discussion addresses pill boxes, smartphone reminders, and blister packs — all of which are irrelevant once the patient is on an LAI. The nonadherence question for an injectable patient is about injection appointment attendance, not pill taking | Reframe the nonadherence section entirely around the LAI context: what does missing an injection appointment mean clinically, how does the provider identify it early, what is the re-initiation protocol, and what is the alternative if the patient refuses injections entirely |
| 5 | Omitting the mother from the education and collaboration section | The mother is explicitly present in the case — she has been accidentally harmed, she is clearly the primary support person, and she is a key target for safety planning and medication coordination. Omitting her from the collaboration section misses a case-specific requirement | Name the mother explicitly in the family education section. Describe what you would tell her, what warning signs you would ask her to watch for, and what safety plan you would put in place given the history of behavioral dyscontrol during psychosis |
| 6 | Fewer than five peer-reviewed references, or references that are course materials | The assignment explicitly requires five peer-reviewed, evidence-based references outside of course resources. Using textbooks, course slides, or non-peer-reviewed sources does not meet this requirement regardless of their quality | Search PubMed, PsycINFO, or CINAHL for paliperidone palmitate long-acting injectable, treatment-resistant schizophrenia criteria, metabolic monitoring antipsychotics, and medication adherence in schizophrenia. Each section of the paper should have at least one cited evidence source supporting the clinical claims made |
FAQs: Schizophrenia Prescribing Assignment
What Your Instructor Is Looking For in a Strong Paper
This assignment is testing three things at once: whether you can make a clinically sound prescribing decision and defend it with evidence-based reasoning; whether you can build a complete clinical plan — including dosing, monitoring, education, collaboration, and contingency — around that decision; and whether you understand how to write accurate mock prescriptions that reflect real-world prescribing requirements. A paper that excels at medication selection but skips the nonadherence plan, or that provides detailed patient education but produces incomplete mock prescriptions, is not demonstrating the full competency the assignment assesses.
The students who score highest treat each section as a clinical document, not a homework section. The dosing section reads like a real initiation protocol. The education section reads like a real medication counseling session. The nonadherence plan reads like a real contingency protocol developed before the first injection is given. The mock prescriptions look like something a pharmacist could actually fill. That level of specificity is what separates high-scoring papers from competent but generic ones.
If you need professional support — writing the paper, reviewing a draft before submission, ensuring all eight requirements are addressed, or formatting your mock prescriptions correctly — the team at Smart Academic Writing covers psychiatric nursing, PMHNP assignments, and pharmacology papers at all levels. Visit our nursing assignment help service, our research paper writing service, our editing and proofreading service, or our discussion post writing service. You can also read how our service works or contact us directly with your assignment details and deadline.